Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

gender (1)


Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 2 records in total 2
    records per page




    Impact of COVID-19 on outpatient therapy with iloprost for Systemic Sclerosis MESHD digital ulcers HP ulcers MESHD

    Authors: Francesca Crisafulli; Maria-Grazia Lazzaroni; Stefania Zingarelli; Mara Rossi; Angela Tincani; Franco Franceschini; Paolo Airò

    doi:10.21203/rs.3.rs-40017/v1 Date: 2020-07-03 Source: ResearchSquare

    Introduction and objectivesThe outbreak of COVID-19 epidemic imposed temporary changes in the management of patients with chronic diseases MESHD. We analyzed the impact of COVID-19 epidemic in patients with Systemic Sclerosis MESHD (SSc) receiving intravenous iloprost infusions for digital ulcers HP ulcers MESHD (DU) treatment.MethodsDuring the epidemic, iloprost infusion therapy in our Hospital was guaranteed; patients were regularly contacted by telephone before the scheduled infusions. DU were evaluated with DUCAS (DU Clinical Assessment Score).ResultsBetween 20th February and 31st May 2020, 47/64 SSc patients did not receive at least one of the scheduled infusions, for patients fear and/or logistical difficulties (43 cases), COVID-19 (2), or other intercurrent diseases MESHD (2). At the last evaluation before 20th February DUCAS was not different between patients who stopped the therapy and those who continued it. The 2 groups had similar rate of new DU during the emergency MESHD period, but DUCAS slightly increased during therapy discontinuation, decreasing after resuming it. After COVID-19, one patient underwent a fingertip sub-amputation, and an 85-year-old male TRANS with multiple comorbidities died for complications related to the infection MESHD.ConclusionsMost SSc patients briefly discontinued iloprost therapy, without increase of new DU number, but with a slight increase of their severity. The regular telephonic contact helped the management that, although not optimal, was adapted to the needs of the individual patient during this emergency MESHD period. DUCAS proved to be a useful tool for rheumatologists. COVID-19 had serious consequences in the two patients who contracted it.

    Comparison of Mental Health Symptoms Prior to and During COVID-19 among Patients with Systemic Sclerosis MESHD from Four Countries: A Scleroderma HP Patient-centered Intervention Network (SPIN) Cohort Study

    Authors: Brett D. Thombs; Linda Kwakkenbos; Richard S. Henry; Marie-Eve Carrier; Scott Patten; Sami Harb; Angelica Bourgeault; Lydia Tao; Susan J. Bartlett; Luc Mouthon; John Varga; Andrea Benedetti; - SPIN Patient Advisors; - SPIN Investigators

    doi:10.1101/2020.06.13.20128694 Date: 2020-06-16 Source: medRxiv

    Background: No studies have reported comparisons of mental health symptoms prior to and during COVID-19 in vulnerable populations. Objectives were to compare anxiety HP and depression symptoms among people with a pre-existing medical condition, the autoimmune disease MESHD systemic sclerosis MESHD (SSc; scleroderma HP), including continuous change scores, proportion with change [≥] 1 minimal clinically important difference (MCID), and factors associated with changes, including country. Methods: Pre-COVID-19 Scleroderma HP Patient-centered Intervention Network Cohort data were linked to COVID-19 data collected April 9 to April 27, 2020. Anxiety HP symptoms were assessed with the PROMIS Anxiety HP 4a v1.0 scale (MCID = 4 points) and depression symptoms with the Patient Health Questionnaire-8 (MCID = 3 points). Multiple linear and logistic regression were used to assess factors associated with continuous change and change [≥] 1 MCID. Findings: Among 435 participants (Canada = 98; France = 159; United Kingdom = 50; United States = 128), mean anxiety HP symptoms increased 4.9 points (95% confidence interval [CI] 4.0 to 5.7). Depression symptom change was negligible (0.3 points; 95% CI -0.7 to 0.2). Compared to France, adjusted scores from the United States and United Kingdom were 3.8 points (95% CI 1.7 to 5.9) and 2.9 points higher (95% CI 0.0 to 5.7); scores for Canada were not significantly different. Odds of increasing by [≥] 1 MCID were twice as high for the United Kingdom (2.0, 95% CI 1.0 to 4.2) and United States (1.9, 95% CI 1.1 to 3.2). Participants who used mental health services pre-COVID had adjusted increases 3.7 points (95% CI 1.7 to 5.7) less than other participants. Interpretation: Anxiety HP symptoms, but not depression symptoms, increased dramatically during COVID-19 among people with a pre-existing medical condition. Increase was larger in the United Kingdom and United States than in Canada and France but substantially less for people with pre-COVID-19 mental health treatment.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.